1. P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. (2nd July 2019) Authors: Rimassa, L; Cheng, A; Braiteh, F; Benzaghou, F; Hazra, S; Borgman, A; Sinha, R; Kayali, Z; Zhu, A; Kelley, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. (13th September 2018) Authors: Colevas, A D; Bahleda, R; Braiteh, F; Balmanoukian, A; Brana, I; Chau, N G; Sarkar, I; Molinero, L; Grossman, W; Kabbinavar, F; Fassò, M; O'Hear, C; Powderly, J Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 199TiPPhase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. (24th November 2019) Authors: Yau, T; Rimassa, L; Cheng, A-L; Park, J-W; Braiteh, F; Chaudhry, A; Benzaghou, F; Thuluvath, P; Hazra, S; Milwee, S; Tan, B; Sinha, R; Kayali, Z K; Zhu, A X; Kelley, R K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer. (1st November 2019) Authors: Allan, S; Braiteh, F; Calvo Aller, E; Cervantes, A; Edenfield, W; Li, T; Rasschaert, M; Park-Simon, T-W; Longo, F; Paz-Ares, L; Spira, A; Strauss, J; Ojalvo, LS; Helwig, C; Dussault, I; Gulley, JL Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC). (13th November 2020) Authors: Naumann, R; Braiteh, F; Diaz, J; Hamilton, E; Diab, S; Schilder, R; Moroney, J; Martin, L; Uyar, D; O'Malley, D; Penson, R; DiLea, C; Palumbo, M; DeAlmeida, V; Berman, C; Matheny, S; Molina, A Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Right ventricular acrylic cement embolism: late complication of percutaneous vertebroplasty. Issue 4 (28th January 2009) Authors: Braiteh, F; Row, M Journal: Heart Issue: Volume 95:Issue 4(2009) Page Start: 275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗